Bonesupport Holding AB

BONEX

SE0009858152

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 11:29:38 2024-05-21 am EDT			5-day change	1st Jan Change
251 ^SEK	+2.70%		+7.36%	+33.37%

Apr. 25	Transcript : Bonesupport Holding AB, Q1 2024 Earnings Call, Apr 25, 2024
Apr. 25	Bonesupport Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Vikram Johri to Leave His Role as GM & EVP Commercial Operations Eurow and Bonesupport as of 24 April 2019

April 24, 2019 at 11:30 am EDT

BONESUPPORT™ announced that Vikram Johri will leave his role as GM & EVP Commercial Operations Eurow and BONESUPPORT as of 24 April 2019. On an interim basis all positions having reported into the GM & EVP Commercial Operations Eurow will report directly into the CEO.

Latest news about Bonesupport Holding AB

Transcript : Bonesupport Holding AB, Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
Bonesupport Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Nordic Shares Decreased Friday; BoneSupport Holding Posted Biggest Loss	Mar. 15	DJ
Nordic Stocks Moved Upward Thursday; Scatec Climbed Highest	Mar. 14	DJ
Bonesupport’s Orthopedic Medical Device for Open Fractures Gains US FDA Nod	Mar. 14	MT
Nordic Shares Moved Upward Wednesday; BoneSupport Holding Topped Leaders	Mar. 06	DJ
Bonesupport Holding AB Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs	Feb. 23	CI
Nordic Stocks Closed Up Monday; Tele2 Series a Topped Leaders	Feb. 19	DJ
Nordic Stocks Closed Up Friday; Yubico Led Increases	Feb. 16	DJ
Bonesupport Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Bonesupport Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Transcript : Bonesupport Holding AB, 2023 Earnings Call, Feb 15, 2024	Feb. 15
Transcript : Bonesupport Holding AB - Analyst/Investor Day	Nov. 28
Bonesupport Holding AB Provides Sales Guidance for the Year 2024	Nov. 28	CI
Bonesupport Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Transcript : Bonesupport Holding AB, Nine Months 2023 Earnings Call, Oct 26, 2023	23-10-26
Bone Support Receives ?Breakthrough Device Designation? for Cerament® V for the Indication of Bone Infection	23-10-16	CI
Transcript : Bonesupport Holding AB, Q2 2023 Earnings Call, Jul 13, 2023	23-07-13
Bonesupport Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-13	CI
Bonesupport Holding AB Launches Next Generation of CeramentÂ® G	23-06-29	CI
BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures	23-05-25	CI
Transcript : Bonesupport Holding AB, Q1 2023 Earnings Call, Apr 27, 2023	23-04-27
Bonesupport Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Transcript : Bonesupport Holding AB, 2022 Earnings Call, Feb 16, 2023	23-02-16
Bonesupport Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16	CI

Chart Bonesupport Holding AB

Duration

Period

More charts

Company Profile

Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.

Sector

Pharmaceuticals

Calendar

2024-07-11 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Bonesupport Holding AB

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

244.4 SEK

Average target price

292.7 SEK

Spread / Average Target

+19.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BONESUPPORT HOLDING AB	+33.37%	1.5B
CSL LIMITED	-3.15%	89.69B
SAMSUNG BIOLOGICS CO.,LTD.	+2.50%	41.34B
BIOGEN INC.	-12.41%	33.72B
UCB	+62.74%	26.11B
BIOMARIN PHARMACEUTICAL INC.	-20.74%	14.63B
INCYTE CORPORATION	-9.11%	12.84B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.34%	11.66B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.92%	11.52B
SWEDISH ORPHAN BIOVITRUM AB	+4.27%	8.92B

Biopharmaceuticals

Bonesupport Holding AB

Equities

BONEX

SE0009858152

Pharmaceuticals

Vikram Johri to Leave His Role as GM & EVP Commercial Operations Eurow and Bonesupport as of 24 April 2019

Latest news about Bonesupport Holding AB

Chart Bonesupport Holding AB

Company Profile

Income Statement Evolution

Ratings for Bonesupport Holding AB

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Biopharmaceuticals